Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that dabrafenib was well tolerated and led to durable responses in patients with BRAF-mutant differentiated thyroid carcinoma, with a median progression-free survival of 11.3 months.

In this study involving women undergoing taxane-based chemotherapy, a twice-daily topical application of BPM31543 was well-tolerated and showed potential in reducing severe hair loss, prompting further investigation at higher doses.

This industry update reports on various advancements in therapeutic delivery during July 2018, highlighting active mergers, collaborations, and potential developments across fields like gene therapy, immuno-oncology, and rare diseases treatment; however, no new clinical results are presented.

This research discusses the parallel clinical development of ritlecitinib, an oral Janus kinase 3/tyrosine kinase inhibitor, for treating conditions such as alopecia areata, vitiligo, ulcerative colitis, Crohn's disease, and rheumatoid arthritis. Results are not reported in the abstract.

This study found that sacituzumab govitecan improved health-related quality of life in most areas for patients with HR+/HER2− metastatic breast cancer compared to chemotherapy, except for increased diarrhea, supporting its use as a treatment option.

The BAYONET trial is a phase II study designed to assess the efficacy and safety of combining encorafenib, binimetinib, and cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer that is resistant to encorafenib plus cetuximab; results are not yet reported.

In this animal study, atorvastatin co-administered with trastuzumab reversed trastuzumab-induced cognitive impairment (chemo-brain) and improved its anti-cancer efficacy without causing hair loss.

The researchers reported that their novel formulation of pterostilbene-loaded ethoniosomes with folic acid coating effectively targeted lung cancer cells in vitro and demonstrated promising results in animal models, indicating potential for future targeted chemotherapy applications.

In this case report, researchers observed that the monoclonal antibody bevacizumab may worsen hypothyroidism in patients, as seen in a 60-year-old woman with metastatic duodenal carcinoma. The authors suggest that thyroid function should be monitored when using VEGF inhibitor therapies due to potential adverse effects.

This review highlights the potential of PROTACs to transform cancer treatment by selectively degrading oncogenic proteins, overcoming drug resistance, and reducing toxicity; it also discusses challenges in optimizing these therapies for personalized applications.

This study found that AR/VDR-targeted agonist hormone therapy can inhibit cell viability in HR2-av triple-negative breast cancer cell lines through multiple mechanisms and may enhance the effects of chemotherapy.

This review discusses fixed drug eruption (FDE) potentially linked to finasteride and emphasizes dermatologists' need to recognize its possible occurrence due to the drug's widespread use, but reports no new clinical results.

This study found that vinblastine treatment rapidly increased platelet counts in childhood refractory immune thrombocytopenia, providing effective control of bleeding symptoms, although side effects like neuropathic pain were common and resolved with dose adjustments.

This study found that FOLFOX6 chemotherapy significantly decreased serum VEGF and CRP levels in advanced colorectal cancer patients, improved their quality of life as measured by KPS scores, and demonstrated a high overall therapeutic efficacy of 82.72% with manageable side effects.

Tofacitinib might be used to treat hair loss.

This study found that the novel drug VDC-1101 showed a 45% objective response rate in treating canine cutaneous T-cell lymphoma, offering a potential treatment option for this challenging disease.

In a mouse model study, transcutaneous auricular vagus nerve stimulation (taVNS) significantly reduced depigmentation in vitiligo, potentially through mechanisms that regulate oxidative stress and inflammation, indicating taVNS's promise as a therapeutic approach for this skin disorder.

This study identified known and potential novel adverse events, such as squamous cell carcinoma and dehydration, for vismodegib, underlining the importance of monitoring especially in the first two months of treatment.

This study found that Imuvert consistently protected against alopecia induced by certain chemotherapy drugs in rats, potentially mediated by a monocyte-derived cytokine like interleukin-1.

This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.

This article discusses the potential of intralesional cidofovir as a treatment for SCC and reports no systemic toxicity, but highlights surgical excision as the most reliable curative option.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

This study found that applying 5% topical minoxidil gel on treatment-resistant vitiligo patches may promote early repigmentation, showing significant improvement at one month compared to a placebo, though later differences were not statistically significant.

In this study, topical tofacitinib significantly increased hair regrowth in mice compared to minoxidil or vehicle, potentially due to elevated VEGF levels and reduced inflammation.

This article suggests using nicotinamide and minoxidil as potassium channel activators to target solid tumors, but reports no new clinical results and calls for further research.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

This study found that a chemotherapy regimen combining CMFVP and ACP treatments for unresectable metastatic breast cancer yielded a 66.7% overall response rate, with premenopausal women responding more favorably than postmenopausal women.

In a preclinical mouse model, this study found that early treatment with the selective SYK inhibitor entospletinib significantly improved survival rates and clinical outcomes for graft-versus-host disease after hematopoietic stem cell transplantation compared to placebo.